ConductScience.org, home

Paper25758528

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Niederst MJ and 26 others. Nat Commun, 2015. Cited by 558 papers, by iCite.

Cite this record

ConductScience Library. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Papers, record 25758528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25758528

Download JSON
Cell line
MGH1213 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
PubMed
Journal
Nat Commun
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
558
iCite
Relative citation ratio, by iCite
14.4
iCite
Revised in PubMed
2022-04-09
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Niederst MJMatthew J
2Sequist LVLecia V
3Poirier JTJohn T
4Mermel CHCraig H
5Lockerman ELElizabeth L
6Garcia ARAngel R
7Katayama RRyohei
8Costa CCarlotta
9Ross KNKenneth N
10Moran TTeresa
11Howe EEmily
12Fulton LELinnea E
13Mulvey HEHillary E
14Bernardo LALindsay A
15Mohamoud FFarhiya
16Miyoshi NNorikatsu
17VanderLaan PAPaul A
18Costa DBDaniel B
19Jänne PAPasi A
20Borger DRDarrell R

Source PubMed

See all 27 authorsDownload CSV of authors

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Antineoplastic AgentsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
ErbB ReceptorsMajor topic
Lung NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
Retinoblastoma ProteinMajor topic
Small Cell Lung CarcinomaMajor topic
Adenocarcinoma of Lung
Afatinib
Aniline Compounds
Cell Line, Tumor
Disease Progression
Drug Resistance, Neoplasm
Erlotinib Hydrochloride
Gefitinib
Gene Expression Regulation, Neoplastic
Humans
Lung
Mutation
Proto-Oncogene Proteins c-bcl-2
Quinazolines
Recurrence
Signal Transduction
Sulfonamides
bcl-X Protein

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P50CA090578NCI NIH HHSUnited StatesP50CA090578PubMed and NIHNIH RePORTER
R01 CA137008NCI NIH HHSUnited StatesR01CA137008PubMed and NIHNIH RePORTER
R01CA137008NCI NIH HHSUnited StatesR01CA137008PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P50 CA090578NCI NIH HHSUnited StatesP50CA090578PubMed and NIHNIH RePORTER
R21 CA156000NCI NIH HHSUnited StatesR21CA156000PubMed and NIHNIH RePORTER
5R21CA156000NCI NIH HHSUnited StatesR21CA156000PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03419286Transformation Into Small Cell Lung Cancer : a Mode of Resistance to TreatmentBackground

Source ClinicalTrials.gov

Download CSV of trials

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120573926Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010https://conductscience.org/library/papers/20573926PubMed
220624269MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.J Exp Clin Cancer Res2010https://conductscience.org/library/papers/20624269PubMed
321098728BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.Sci Signal2010https://conductscience.org/library/papers/21098728PubMed
421178714Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.J Thorac Oncol2011https://conductscience.org/library/papers/21178714PubMed
521316603A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.Cancer Cell2011https://conductscience.org/library/papers/21316603PubMed
621430269Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med2011https://conductscience.org/library/papers/21430269PubMed
721791641A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Cancer Res2011https://conductscience.org/library/papers/21791641PubMed
820022809Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol2010https://conductscience.org/library/papers/20022809PubMed
921565397Small-cell lung cancer.Lancet2011https://conductscience.org/library/papers/21565397PubMed
1022071650Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.Ann Oncol2011https://conductscience.org/library/papers/22071650PubMed
1122277784Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Sci Transl Med2012https://conductscience.org/library/papers/22277784PubMed
1222460902Systematic identification of genomic markers of drug sensitivity in cancer cells.Nature2012https://conductscience.org/library/papers/22460902PubMed
1322460905The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature2012https://conductscience.org/library/papers/22460905PubMed
1422496272Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res2012https://conductscience.org/library/papers/22496272PubMed
1522961666Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.Cancer Discov2012https://conductscience.org/library/papers/22961666PubMed
1622941188Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.Nat Genet2012https://conductscience.org/library/papers/22941188PubMed
1722941189Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.Nat Genet2012https://conductscience.org/library/papers/22941189PubMed
1823401451Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.J Clin Oncol2013https://conductscience.org/library/papers/23401451PubMed
1923470965Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Clin Cancer Res2013https://conductscience.org/library/papers/23470965PubMed
2023816960Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol2013https://conductscience.org/library/papers/23816960PubMed

See all 34 referencesDownload CSV of references

Cited by401

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 558 citations.

PMIDTitleJournalYearIn PapersSource
42953404Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.Front Cell Dev Biol2026https://conductscience.org/library/papers/42953404PubMed
42844350Cell plasticity in cancer and therapy resistance.Exp Mol Med2026https://conductscience.org/library/papers/42844350PubMed
42836273Genes, fuel, and fate in lung cancer.Biochem Soc Trans2026https://conductscience.org/library/papers/42836273PubMed
42816600Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nat Genet2026https://conductscience.org/library/papers/42816600PubMed
42761714Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection.Front Immunol2026https://conductscience.org/library/papers/42761714PubMed
42757013Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma.Front Genet2026https://conductscience.org/library/papers/42757013PubMed
42724635Advanced and underlying therapeutic strategies in transformed small cell lung cancer.Front Med (Lausanne)2026https://conductscience.org/library/papers/42724635PubMed
42611544Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation.J Clin Invest2026https://conductscience.org/library/papers/42611544PubMed
42603101Epigenetic reprogramming of lineage switching in cancer.FEBS Lett2026https://conductscience.org/library/papers/42603101PubMed
42572587Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer.iScience2026https://conductscience.org/library/papers/42572587PubMed
42570967Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma.Br J Cancer2026https://conductscience.org/library/papers/42570967PubMed
42512348Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review.Cancers (Basel)2026https://conductscience.org/library/papers/42512348PubMed
42490143PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression.J Clin Invest2026https://conductscience.org/library/papers/42490143PubMed
42483566Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.Immunotargets Ther2026https://conductscience.org/library/papers/42483566PubMed
42450152Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.Int J Mol Sci2026https://conductscience.org/library/papers/42450152PubMed
42447248Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.Oncologist2026https://conductscience.org/library/papers/42447248PubMed
42444834Unmasking biomarkers in small cell lung cancer: implication for precision oncology.Front Oncol2026https://conductscience.org/library/papers/42444834PubMed
42290055[A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment].Zhongguo Fei Ai Za Zhi2026https://conductscience.org/library/papers/42290055PubMed
42088420A Darwinian Perspective on Tumor Evolution.Int J Biol Sci2026https://conductscience.org/library/papers/42088420PubMed
42079860The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability.Explor Target Antitumor Ther2026https://conductscience.org/library/papers/42079860PubMed

See all 401 cited byDownload CSV of cited by

Genes21

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
CDH1999PubTator's text mininghttps://conductscience.org/library/genes/999NCBI Gene
CHGA1113PubTator's text mininghttps://conductscience.org/library/genes/1113NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF2AK39451PubTator's text mininghttps://conductscience.org/library/genes/9451NCBI Gene
FGFR12260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
NCAM14684PubTator's text mininghttps://conductscience.org/library/genes/4684NCBI Gene
NEUROD14760PubTator's text mininghttps://conductscience.org/library/genes/4760NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene
RB15925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene
RNU6-6P26826PubTator's text mininghttps://conductscience.org/library/genes/26826NCBI Gene
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene
SYP6855PubTator's text mininghttps://conductscience.org/library/genes/6855NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

See all 21 genesDownload CSV of genes

Data3

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccessionSource
GEOGSE64322GEO
GEOGSE64765GEO
GEOGSE64766GEO

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25758528

GET https://conductscience.org/api/papers/v1/25758528/authors?page=2